cyclomedica
technegas

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

11 June 2025

CYCLOPHARM SECURES MAXIMUM U.S. PATENT EXTENSION FOR TECHNEGAS® TO 2031

Cyclopharm Limited (ASX: **CYC**) is pleased to announce that the United States Patent and Trademark Office (**USPTO**) has **granted the maximum allowable patent term extension of five years** covering the TECHNEGAS® Kit (technetium Tc-99m labelled carbon) to 2031.

This milestone follows a **comprehensive review by both the USPTO and the U.S. Food and Drug Administration (FDA)**, which confirmed that the patent covering TECHNEGAS® qualified for a term extension under 35 U.S.C. § 156. As a result, the original patent, previously set to expire in 2026, has now been extended to 2031. The five-year extension granted represents the maximum duration permitted under U.S. law.

Significance to Shareholders and Strategic Positioning

This patent extension provides uninterrupted United States market exclusivity for TECHNEGAS® through to early 2031, underscoring a **significant competitive advantage** and ensuring a clear runway for value creation in the **world's largest healthcare market**. It allows Cyclopharm to fully realise the commercial and clinical potential of TECHNEGAS® in the United States in both diagnosing Pulmonary Embolism and a growing number of indications *Beyond PE* without the risk of near-term generic or biosimilar competition.

The FDA's thorough regulatory review and continued support during the patent extension process highlight the strong and differentiated clinical profile of TECHNEGAS®. This further reinforces TECHNEGAS®'s position as **the leading nuclear medicine agent for functional lung ventilation imaging**.

Cyclopharm Managing Director, James McBrayer, commented: *"The granting of the maximum allowable U.S. patent term extension is a significant achievement for TECHNEGAS®. This outcome reflects several years of diligent and strategic work that has been progressing in the background while we worked toward U.S. FDA regulatory approval. It validates our long-term commitment to protecting the value of our technology and provides a strong foundation as we accelerate our U.S. commercialisation efforts with additional business development personnel."*

Ongoing Innovation Beyond 2031

While the patent extension and its associated market exclusivity are significant positives for the company, Cyclopharm also continues to actively invest in a broader range of initiatives to extend protection for the TECHNEGAS® platform and pipeline well beyond 2031. These include new patent filings, next-generation developments and complementary intellectual property initiatives designed to ensure Cyclopharm's continued leadership in pulmonary imaging and related respiratory technologies.

Cyclopharm remains committed to delivering superior outcomes for patients, clinicians, and shareholders alike through its expanding clinical footprint, strategic partnerships, and reinforced IP portfolio.

ENDS -

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director and CEO.

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

Cyclopharm Limited

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas® used in functional lung ventilation imaging.

Technegas®

Cyclopharm's Technegas® technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700^{o} C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas®, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other ***Beyond PE*** disease states to include COPD, asthma, pulmonary hypertension, Long COVID and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.

In the United States the Technegas approved indication for use for use is:
TECHNEGAS, when used with sodium pertechnetate Tc 99m in the Technegas Plus System, provides technetium Tc 99m-labeled carbon inhalation aerosol (Technegas Aerosol), a radioactive diagnostic agent for use in adults and pediatric patients aged 6 years and older is for the visualization of pulmonary ventilation and the evaluation of pulmonary embolism when paired with perfusion imaging.